- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07944560
Development of dEep EndometrioSis Following Acute haemoPerITonEum (DEESPITE)
This study investigates whether acute pelvic pain with haemoperitoneum is associated with an increased risk of developing deep pelvic endometriosis, compared with acute pelvic pain without haemoperitoneum. Women aged 18-50 who attended the Obstetric-Gynecological Emergency Department for acute pelvic pain between January 2020 and December 2024 will be invited to a single follow-up visit, including a transvaginal ultrasound and validated questionnaires.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
This is a single-centre, non-pharmacological, interventional, no-profit study conducted at the Obstetric-Gynecological Emergency Department and the Infertility Unit of Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, Italy.
Women aged 18-50 who attended the Obstetric-Gynecological Emergency Department for acute pelvic pain between January 2020 and December 2024 will be invited to participate. Cases are women with documented haemoperitoneum and no previous diagnosis of endometriosis. Controls are women with acute pelvic pain without haemoperitoneum and no previous diagnosis of endometriosis, matched to cases by age (±2 years) and year of the event (±1 year). Women with previous hysterectomy or oophorectomy, or established menopause, are excluded.
Participants who provide informed consent will attend a single follow-up visit, lasting approximately one hour. The visit includes a second-level transvaginal ultrasound to identify lesions suggestive of deep endometriosis according to the IDEA criteria, and validated questionnaires assessing quality of life (SF-12), endometriosis-specific quality of life (EHP-30), sexual function (FSFI) and pain (NRS).
The primary outcome is the incidence of sonographically diagnosed deep pelvic endometriosis between 6 months and up to 5 years after the acute event, comparing cases and controls. Secondary outcomes include the impact of the acute event on chronic pelvic pain and quality of life, and the association between treatment of the acute event (surgical vs conservative) or use of hormonal therapy during follow-up and the development of endometriosis.
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Edgardo Somigliana, PhD
- Telefonnummer: +39 0255034311
- E-Mail: procreazioneassistita@policlinico.mi.it
Studieren Sie die Kontaktsicherung
- Name: Marco Reschini, MSc
- Telefonnummer: +39 0255034311
- E-Mail: procreazioneassistita@policlinico.mi.it
Studienorte
-
-
MI
-
Milan, MI, Italien, 20122
- Rekrutierung
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
-
Kontakt:
- Edgardo Somigliana, PhD
- Telefonnummer: +39 0255034311
- E-Mail: procreazioneassistita@policlinico.mi.it
-
Kontakt:
- Marco Reschini, MSc
- Telefonnummer: +39 0255034311
- E-Mail: procreazioneassistita@policlinico.mi.it
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Women aged 18-50 who attended the Obstetric-Gynecological Emergency Department for acute pelvic pain between January 2020 and December 2024
Beschreibung
Inclusion Criteria:
- Women aged 18-50 years
- Female sex
- Attendance at the Obstetric-Gynecological Emergency Department (Clinica Mangiagalli) for acute pelvic pain
- For cases: documented haemoperitoneum without a previous diagnosis of endometriosis
- For controls: no documented haemoperitoneum without a previous diagnosis of endometriosis
Exclusion Criteria:
- Previous hysterectomy and/or oophorectomy
- Established menopause
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: CASE_CONTROL
- Zeitperspektiven: PROSPECTIVE
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
Haemoperitoneum
Women aged 18-50 with acute pelvic pain and documented haemoperitoneum, without a previous diagnosis of endometriosis |
|
No haemoperitoneum
Women aged 18-50 with acute pelvic pain and no documented haemoperitoneum, without a previous diagnosis of endometriosis, matched to cases by age (±2 years) and year of the event (±1 year) |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of sonographically diagnosed deep pelvic endometriosis
Zeitfenster: From 6 months up to 5 years after the acute event
|
Incidence of deep pelvic endometriosis diagnosed by second-level transvaginal ultrasound according to IDEA criteria, comparing cases (haemoperitoneum) and controls (no haemoperitoneum) |
From 6 months up to 5 years after the acute event
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Pelvic pain intensity assessed using the Numeric Rating Scale (NRS)
Zeitfenster: From 6 months up to 5 years after the acute event
|
Comparison of pelvic pain intensity between participants with and without haemoperitoneum at the index acute event, assessed using the Numeric Rating Scale (NRS). Scores range from 0 (no pain) to 10 (worst imaginable pain), with higher scores indicating greater pain intensity. |
From 6 months up to 5 years after the acute event
|
|
Endometriosis-related quality of life assessed using the Endometriosis Health Profile-30 (EHP-30)
Zeitfenster: From 6 months up to 5 years after the acute event
|
Comparison of the Endometriosis Health Profile-30 (EHP-30) overall summary score between participants with and without haemoperitoneum at the index acute event. The core questionnaire contains 30 items, each scored from 0 to 4. A single overall score is calculated by summing the scores of all 30 items, dividing the sum by the maximum possible score of 120, and multiplying by 100. The overall score ranges from 0 to 100, with higher scores indicating worse health-related quality of life. |
From 6 months up to 5 years after the acute event
|
|
Quality of life assessed using the Short Form Health Survey (SF-12)
Zeitfenster: From 6 months up to 5 years after the acute event
|
Comparison of the 12-Item Short Form Health Survey (SF-12) scores between participants with and without haemoperitoneum at the index acute event. Scores will be calculated using the questionnaire's standard scoring algorithm. Norm-based scores have a reference population mean of 50 and a standard deviation of 10, with higher scores indicating better physical health-related quality of life. |
From 6 months up to 5 years after the acute event
|
|
Sexual function assessed using the Female Sexual Function Index (FSFI)
Zeitfenster: From 6 months up to 5 years after the acute event
|
Comparison of Female Sexual Function Index (FSFI) total scores between participants with and without haemoperitoneum at the index acute event. The FSFI is a 19-item questionnaire assessing six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. Weighted domain scores are summed to obtain a total score ranging from 2 to 36, with higher scores indicating better sexual function. |
From 6 months up to 5 years after the acute event
|
|
Odds ratio for endometriosis diagnosis according to initial treatment
Zeitfenster: From 6 months up to 5 years after the acute event
|
Odds ratio with 95% confidence interval for a diagnosis of endometriosis following the index acute event, comparing participants initially managed surgically with those managed conservatively. Initial treatment will be classified from medical records. Endometriosis diagnosis will be established according to the study diagnostic criteria. The odds ratio will be estimated using logistic regression, with endometriosis diagnosis coded as a binary outcome (yes/no). |
From 6 months up to 5 years after the acute event
|
|
Odds ratio for endometriosis diagnosis according to hormonal therapy use
Zeitfenster: From 6 months up to 5 years after the index acute event.
|
Odds ratio with 95% confidence interval for a diagnosis of endometriosis following the index acute event, comparing participants who received hormonal therapy during follow-up with those who did not. Endometriosis diagnosis will be established according to the study diagnostic criteria. The odds ratio will be estimated using logistic regression, with endometriosis diagnosis coded as a binary outcome (yes/no). |
From 6 months up to 5 years after the index acute event.
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Genitalerkrankungen
- Schmerzen
- Neurologische Manifestationen
- Pathologische Prozesse
- Weibliche Urogenitalerkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Erkrankungen des Verdauungssystems
- Genitalerkrankungen, weiblich
- Blutung
- Peritonealerkrankungen
- Pathologische Zustände, Anzeichen und Symptome
- Anzeichen und Symptome
- Endometriose
- Schmerzen im Beckenbereich
- Hämoperitoneum
Andere Studien-ID-Nummern
- PMA2025_02
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .